Q3 FY26 · Ended Sep 30, 2026 · View SEC filing
Diagnostics alone earns more than the whole company
Both labs widened their margins, but corporate, LaunchPad and deal costs held operating income growth to 1.4%.
For investorsWhat has to go right for reported margin to follow the segments
For foundersPaying for change at the center: the playbook behind LaunchPad
Biopharma Laboratory Services earned more per dollar than Diagnostics, helped by strategic actions in its Early Development business, the filing says.
Organic volume grew more than twice as fast as organic price and mix, and faster than its nine-month pace.
Non-cash depreciation and acquisition amortization lift operating cash well above net earnings, though quarterly cash swings widely.
Unlock the financial breakdown, competitive insights, historical trends and founder playbook, plus research across the company library.
Free CXProWealth membership required
Business Lens describes Labcorp from its own filings with the SEC. It is not a view on its shares, a target, or advice to buy, sell or hold anything; figures are as filed and may be restated by the company later. The filing is linked above.
